A Phase 1 interventional study of Transcranial static magnetic field stimulation (tSMS) of the supplementary motor area in Parkinson's Disease, sponsored by Fundación de investigación HM. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-02-21.
Sponsored by Fundación de investigación HM · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 225 studies in Parkinson Disease with a site in Spain — 37 open to participants now, 56 under way, 3 of them phase 3. Parkinson Disease · Spain.
Among the 225 studies in Parkinson Disease with a site in Spain, this one is the 159th largest by planned enrollment of the 179 interventional ones that give a count, is one of 18 that started in 2022, is one of 7 in phase 1, reaches primary completion later than 14 of the 55 other live ones, and was the 171st registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →37 of the 225 studies in Parkinson Disease with a site in Spain are open now. Recruiting first, the newest first:
University of Valencia · Sites in Spain
Ages 18–99
University Hospital Tuebingen · Sites in Spain, France, Germany and 4 more countries
Ages 35–80
Universidad San Jorge · Sites in Spain
Ages 55–90
AbbVie · Sites in Spain, United States, Canada and 6 more countries
Ages 18–69
University of Vigo · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
225 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 38 · Phase 3 54 · Phase 4 12
First in 2002; this study’s year is marked. 18 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 100 across the 179 interventional studies, 300 across the 45 observational. Of the 153 that completed or were terminated, 60 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
131 of 225 have an industry lead sponsor. The 10 most frequent:
Fundación de investigación HM is the lead sponsor of 23 studies on the registry; 9 are open to participants now.
Fundación de investigación HM has 5 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
13 of the studies in Parkinson Disease with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07780461University of VigoCharacterization and Validation of the Short Physical Performance Battery in Individuals Diagnosed With Parkinson's Disease | 2026-11-25 |
| NCT04788693University of ValenciaEffects of Gait Rehabilitation With Motor Imagery in People With Parkinson's Disease | 2026-12 |
| NCT07842926Universidad San JorgeAcute Effects of Capacitive-Resistive Radiofrequency Therapy in People With Parkinson's Disease | 2026-12-01 |
| NCT01799915NYU Langone HealthNatural History Study of Synucleinopathies | 2026-12-30 |
| NCT07284342AbbVieA Study to Assess Change in Sleep Disturbances of Adult Participants With Advanced Parkinson's Disease Receiving Subcutaneous Foslevodopa/Foscarbidopa | 2027-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 225 studies in Parkinson Disease with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a pilot open study to test the hypothesis that home-based transcranial static magnetic field stimulation (tSMS) of the supplementary motor area is safe and feasible to modulate corticostriatal activity in patients with Parkinson's disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
30 min of tSMS, 5 daily sessions per week (monday to friday), for 8 weeks, at home
Device: Transcranial static magnetic field stimulation (tSMS) of the supplementary motor area
Transcranial static magnetic field stimulation (tSMS) is a non-invasive brain stimulation (NIBS) technique that decreases cortical excitability. Static magnetic fields suitable for tSMS are obtained with commercially available neodymium magnets. The investigators will use a cylindrical neodymium magnet of 60 mm diameter and 30 mm of thickness (MAG60r; Neurek SL, Toledo, Spain), which will be applied with south polarity to the supplementary motor area (SMA) using an ergonomic helmet (MAGsv1.1, Neurek SL, Toledo, Spain).
Also known as: MAGsv1.1 with MAG60r, Neurek SL, Toledo, Spain
Adverse events (safety)
Number of device-related AE
Time frame: From the start to 3 months after the end of treatment (5 months)
Feasibility of home-based tSMS
Number of home-based tSMS sessions completed, according to patient's diaries
Time frame: From the start to the end of treatment (8 weeks)
Subjective improvement
Patient global impression of change (PGIC)
Time frame: Within one week after the end of treatment compared to baseline
Motor improvement
MDS-UDPRS III scale
Time frame: Within one week after the end of treatment compared to baseline
Sleep improvement
SCOPA-sleep scale
Time frame: Within one week after the end of treatment compared to baseline
Change in corticospinal excitability
Amplitude of motor evoked potentials (MEPs) evoked by transcranial magnetic stimulation of the motor cortex
Time frame: Within one week after the end of treatment compared to baseline
Changes in corticostriatal activity by FDG-PET
FDG-PET uptake in SMA and motor striatum
Time frame: Within one week after the end of treatment compared to baseline
Changes in corticostriatal activity by resting-state fMRI
Functional connectivity between SMA and motor striatum
Time frame: Within one week after the end of treatment compared to baseline
Changes in corticostriatal microstructure by diffusion-tensor imaging (DTI)
Fractional anisotropy and diffusivity in SMA and motor striatum.
Time frame: Within one week after the end of treatment compared to baseline
Plan to share: No
Started Oct 2022 (actual). Primary completion is estimated for Aug 2025, 34 months after the start.
Of 77 non-industry phase 1 interventional studies under Parkinson Disease, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 68. This study's planned 34 months is close to that.
Counting every sponsor, half of 204 studies reached it within 18 months; a quarter within 5 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación de investigación HM